Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3390/cancers10040115 http://scihub22266oqcxt.onion/10.3390/cancers10040115 C5923370!5923370!29642615     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cancers+(Basel) 2018 ; 10 (4): ä Nephropedia Template TP {{tp|p=29642615|t=2018. YAP/TAZ Activation as a Target for Treating Metastatic Cancer |pdf=|usr=}}{{29642615}} gab.com Text YAP/TAZ Activation as a Target for Treating Metastatic Cancer JO: Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=29642615 #FOAvip Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstrating that YAP or TAZ activation promotes cancer formation, tumor progression, and metastasis. In this review we summarize the evidence linking YAP/TAZ activation to metastasis, and discuss the roles of YAP and TAZ during each step of the metastatic cascade. Collectively, this evidence strongly suggests that inappropriate YAP or TAZ activity plays a causal role in cancer, and that targeting aberrant YAP/TAZ activation is a promising strategy for the treatment of metastatic disease. To this end, we also discuss several potential strategies for inhibiting YAP/TAZ activation in cancer and the challenges each strategy poses. Twit Text FOAVip YAP/TAZ Activation as a Target for Treating Metastatic Cancer ????Cancers (Basel) http://www.kidney.de/pget.php?&tw=1&pmid=29642615 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29642615 #FOAvip English Wikipedia <ref>{{Cite pmid|29642615}}</ref> YAP/TAZ Activation as a Target for Treating Metastatic Cancer #MMPMID29642615 Warren JSA; Xiao Y; Lamar JM Cancers (Basel) 2018[Apr]; 10 (4): ä PMID29642615show ga Yes-Associated Protein (YAP) and Transcriptional Co-activator with PDZ-binding Motif (TAZ) have both emerged as important drivers of cancer progression and metastasis. YAP and TAZ are often upregulated or nuclear localized in aggressive human cancers. There is abundant experimental evidence demonstrating that YAP or TAZ activation promotes cancer formation, tumor progression, and metastasis. In this review we summarize the evidence linking YAP/TAZ activation to metastasis, and discuss the roles of YAP and TAZ during each step of the metastatic cascade. Collectively, this evidence strongly suggests that inappropriate YAP or TAZ activity plays a causal role in cancer, and that targeting aberrant YAP/TAZ activation is a promising strategy for the treatment of metastatic disease. To this end, we also discuss several potential strategies for inhibiting YAP/TAZ activation in cancer and the challenges each strategy poses. äYAP/TAZ Activation as a Target for Treating Metastatic Cancer (epmc).pdf DeepDyve Pubget Overpricing